Macrocycles in Drug Discovery
Jeremy Levin
αα»ααΆ 2014 Β· Drug Discovery Series ααααα
ααΈ 40 Β· Royal Society of Chemistry
ααααα
βα’αα‘α·α
ααααΌαα·α
528
ααααα
reportααΆαααΆαααααα αα·αααα·ααΆαααααααα·αααααΌαααΆααααααααααΆαααα αααααααααααααα
α’αααΈααααα βα’αα‘α·α ααααΌαα·αααα
This book reviews macrocycles in drug discovery, both those of natural origin and semi-synthetic derivatives of natural products, and those designed and synthesized based on principles of medicinal chemistry.
The medicinal chemistry of macrocyclic natural products is interesting in itself, but lessons learned from these compounds, in terms of the relationship between structure and desirable physicochemical properties, are now informing the design of fully synthetic macrocyclic drug candidates against a variety of targets including kinases, ATPases, proteases, GPCRs and others. Furthermore, as more non-classical drug targets, such as proteinβprotein interactions, are pursued in the pharmaceutical industry, macrocyclic molecules are generating increasing interest as they offer a way to provide drugβprotein interactions that cover a larger surface area than traditional small molecules.
A variety of macrocycles have become important drugs or have been identified as leads to marketed drugs. This text will discuss these compounds, their pharmacology and synthesis, in the context of their broad chemotype as compounds composed of large rings. Providing a wide reaching review of this important area in a single volume, this book will be of interest to biochemists, pharmaceutical scientists and medicinal chemists working in industry or academia.
The medicinal chemistry of macrocyclic natural products is interesting in itself, but lessons learned from these compounds, in terms of the relationship between structure and desirable physicochemical properties, are now informing the design of fully synthetic macrocyclic drug candidates against a variety of targets including kinases, ATPases, proteases, GPCRs and others. Furthermore, as more non-classical drug targets, such as proteinβprotein interactions, are pursued in the pharmaceutical industry, macrocyclic molecules are generating increasing interest as they offer a way to provide drugβprotein interactions that cover a larger surface area than traditional small molecules.
A variety of macrocycles have become important drugs or have been identified as leads to marketed drugs. This text will discuss these compounds, their pharmacology and synthesis, in the context of their broad chemotype as compounds composed of large rings. Providing a wide reaching review of this important area in a single volume, this book will be of interest to biochemists, pharmaceutical scientists and medicinal chemists working in industry or academia.
α’αααΈβα’ααααα·αααα
Jeremy Levin is currently a Director of Medicinal Chemistry at Boehringer Ingelheim Pharmaceuticals, with a total of 25 years of experience in the pharmaceutical industry. He has worked in multiple therapeutic areas, including CNS, inflammation and immunology, and oncology. Dr Levin has authored or co-authored more than 70 papers in peer reviewed journals and served as an inventor on more than 60 issued U.S patents.
ααΆααααααααααα βα’αα‘α·α ααααΌαα·αααα
ααααΆααααΎαα’αααΈααΆααααααΎαααααα’αααα
α’αΆαβααααααΆα
ααΌαααααααααΆααα αα·αβααααααα
ααα‘αΎααααααα·ααΈ Google Play Books αααααΆαα Android αα·α iPad/iPhone α ααΆβααααΎααααΆαααααβαααααααααααααααα·ααΆαα½αβααααΈβααααα’αααβ αα·αβα’αα»ααααΆαα±ααβα’αααα’αΆααααβααΆαα’ααΈαααΊαα·α α¬ααααΆαβα’ααΈαααΊαα·αβαα
αααααααΈααααααα
αα»αααααΌαααβαα½ααα αα·ααα»αααααΌααα
α’αααα’αΆα
ααααΆααααααα
ααΆααα‘αααααααΆααα·ααα
αααα»α Google Play αααααααΎαααααα·ααΈαα»αααααΆαα’ααΈαααΊαα·ααααα»ααα»αααααΌαααααααα’αααα
eReaders αα·αβα§αααααβαααααβααα
ααΎααααΈα’αΆααα
ααΎβα§ααααα e-ink ααΌα
ααΆβα§αααααα’αΆαβααααα
α’αα‘α·α
ααααΌαα·α Kobo α’αααααΉαααααΌαβααΆαααβα―αααΆα α αΎαβαααααααΆαα
βα§αααααβααααα’αααα ααΌαα’αα»ααααααΆαβααΆαααααΆααααα’α·αααααααααααααααααα½α ααΎααααΈαααααα―αααΆαβαα
α§αααααα’αΆαααααα
βα’αα‘α·α
ααααΌαα·ααααααααΆααα
